Catalog

MaxCyte® Product Catalog

Complete product list for scalable cell engineering and gene editing analytics.

Row herosectionWave Shape Decorative svg added to top

Explore the MaxCyte product catalog for a complete view of our portfolio supporting cell and gene therapy development. From ExPERT™ electroporation instruments and processing assemblies to SeQure™ gene editing risk assessment services, this catalog brings together the products and capabilities designed to support discovery, process development, manufacturing, and regulatory-aligned development.

ExPERT Systems

Explore the ExPERT DTx™, ATx®, STx®, GTx®, and VLx™ instrument portfolio, supporting applications from small-scale discovery to GMP manufacturing and gram-scale protein production.

Processing Assemblies & Consumables

Review RUO and GMP processing assemblies across a broad range of volumes and formats, from multiwell screening workflows to Flow Electroporation® applications.

Buffers & Accessories

Find electroporation buffers, buffer bags, racks, starter packs, and workflow accessories designed to support efficient, reproducible operation across the MaxCyte platform.

SeQure™ Assays & Services

Discover SeQure™ screening, nomination, and confirmation assays for comprehensive, regulatory-aligned gene editing safety and genotoxicity risk assessment.

Related Resources

Thumbnail for SeQure DX FDA-aligned risk assessment scientific brief

SeQure™ Risk Assessment Services Align with FDA Guidance for Gene-Edited Human Gene Therapy Products

Our SeQure screening assays offer early insights into on- and off-target editing, addressing FDA and other regulatory expectations during guide design to reduce risk, streamline development and accelerate your path to the clinic.
First page screenshot of application note pdf.

MaxCyte® Enabled Mammalian Display Method for the Development of Enhanced Affinity TCR-Based Biologics

MaxCyte electroporation enabled the development of a Flp landing pad CHO cell line, the generation of a TCER CHO library and the production of biologically active soluble TCER candidates by transient gene expression.

MaxCyte® Enables a cGMP-Compatible Manufacturing Process for Highly Efficient T Cell Engineering

Excitement over recent breakthroughs in autologous cellular therapies has been tempered by the expense of manufacturing with viral gene delivery and concerns over random integration and the safety of viral vectors.